PROCEPT BioRobotics (PRCT) said Monday that an independent trial showed its aquablation therapy provided similar symptom relief, with superior ejaculatory function and continence preservation compared to laser enucleation for treating large prostates.
The company said the study, which treated 186 men, showed positive results for the three-month primary safety and efficacy endpoints, with long-term follow-up planned for up to five years.
The aquablation therapy arm also reported a 0% transfusion rate, highlighting the therapy's safety and effectiveness in minimizing bleeding risks, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.